Lower prescription drug costs by cracking down on tactics big pharma uses to block cheaper generic drugs from entering the market.

introduced the bipartisan STOP GAMES Act ... The legislation aims to crack down on tactics used by big pharma to block cheaper, generic drugs from entering the market.

Sorensen says he introduced legislation to reduce prescription drug costs by stopping anti-generic blocking tactics.

Representative Eric Sorensen | Your Trusted Neighbor in Congress
primary · press_release · model gpt-5.4-mini

My bipartisan STOP GAMES Act will crack down on tactics that Big Pharma uses to prevent cheaper, generic drugs from coming to market.

Sorensen commits to advancing legislation that blocks anti-generic tactics used by big pharma.

Congressman Sorensen Introduces Plan to Put Money Back in Your Pocket | Representative Eric Sorensen
primary · press_release · model gpt-5.4-mini

"I am so proud to be leading the bipartisan STOP GAMES Act," ... "This bill would crack down on Big Pharma while giving my neighbors the option to buy generic drugs, which can drive down costs by up to 95%."

Sorensen says he is leading the STOP GAMES Act to crack down on tactics that block generic drugs and lower prescription drug costs.

Sorensen Introduces Bipartisan Legislation to Lower Prescription Drug Costs | Representative Eric Sorensen
primary · press_release · model gpt-5.4-mini

“I’m fighting to lower prescription drug costs by protecting and expanding Medicare's ability to negotiate drug prices, and I have a bill to stop Big Pharma’s price gouging that is preventing cheaper generics from getting onto pharmacy shelves.”

Sorensen publicly claims active legislative work aimed at blocking tactics that keep cheaper generics off the market, which directly matches the claim. This is advocacy/evidence of effort, not proof of enactment or final delivery.

unresolved same_term A for effort

Lowering Costs for Illinoisans | Representative Eric Sorensen
secondary · model gpt-5.4-mini · confidence 83%

“My bill, the STOP GAMES Act, addresses their tactic. STOP GAMES cracks down on citizen petitions filed not to improve safety, but to delay competition. Often filed at the last minute, these duplicative and unsupported petitions stall generic approvals for years, all the while keeping prices high for patients... STOP GAMES gives the FDA clear authority to quickly reject petitions whose...”

Sorensen restated the core anti-delay theory behind the claim and identified a concrete bill he says would crack down on those tactics. This shows continuing effort but not final legislative delivery in the lookback window.

unresolved same_term A for effort

Statement of Representative Eric Sorensen (House Committee on Energy and Commerce Member Day)
secondary · model gpt-5.4-mini · confidence 86%

Sponsor: Rep. Sorensen, Eric [D-IL-17] (Introduced 04/28/2023). Latest Action: House - 05/05/2023 Referred to the Subcommittee on Health. Tracker: Tip | This bill has the status Introduced.

The bill Sorensen introduced to stop petition-based delays in generic drug entry was introduced and referred, but there is no evidence here of enactment. This is the strongest official record for the underlying tactic-targeting legislation, but it indicates no delivery to law.

never same_term A for effort

H.R.3030 - STOP GAMES Act of 2023
secondary · model gpt-5.4-mini · confidence 95%

“These ‘pay-for-delay’ patent settlements effectively block all other generic drug competition for a growing number of branded drugs.” The FTC says it supports legislation to end such anticompetitive settlements.

FTC confirms the existence of the exact kind of market-blocking tactic Sorensen’s claim targets. This supports the policy rationale and shows the problem remains real, but it does not show Sorensen’s specific promise was fulfilled.

unresolved same_term

Pay for Delay | Federal Trade Commission
secondary · model gpt-5.4-mini · confidence 78%

“Section 505(q) was added to the FD&C Act in 2007 to limit the potential for certain citizen petitions to be employed as a means to delay approval of generic and certain other applications.”

FDA acknowledges the anti-delay mechanism Sorensen’s claim refers to and explains the statutory purpose. Helpful context, but it is older background rather than recent proof of a completed Sorensen achievement.

unresolved same_term

Antitrust Concerns and The FDA Approval Process | FDA
secondary · model gpt-5.4-mini · confidence 90%